Latest total revenue for CDXC: $57M, below the Healthcare sector average of $12T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest total revenue for CDXC is $57M as of September 2026. That compares with $29M in the prior-year period — up 95.6% year over year. That is below the Healthcare sector average of $12T. Investors often review this figure alongside Chromadex's historical trend and sector peers before judging valuation or financial health.
Over the past year, CDXC's total revenue moved from $29M to $57M — a 95.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chromadex's operating scale or balance-sheet position.
Against Healthcare companies, CDXC currently prints $57M for total revenue, while the sector average sits near $12T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Chromadex's growth, margins, and balance sheet.
A total revenue figure of $57M for CDXC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $12T. Explore the charts below for those layers of context.
After noting CDXC's total revenue ($57M), review year-over-year change from $29M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.